NCT01400568View on ClinicalTrials.gov

Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Healthy
Interventions
DRUG

LPS challenge with nebulized LPS

20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.

DRUG

fluticasone propionate (FP)

The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.

Trial Locations (1)

30625

Fraunhofer ITEM, Hanover

All Listed Sponsors
lead

Fraunhofer-Institute of Toxicology and Experimental Medicine

OTHER

NCT01400568 - Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model | Biotech Hunter | Biotech Hunter